4SC AG and Sanwa Kagaku Kenkyusho Co., Ltd. have announced that they have achieved the first milestone and entered the next phase of their drug discovery collaboration which was started in January 2005.
To date 4SC has applied its proprietary virtual High Throughput Screening technology, 4SCan® to identify active agents against specific targets provided by SKK, followed by corresponding biological screening experiments.
A dedicated team of 4SC scientists shall now further optimize hits and leads with respect to certain properties like potency, selectivity and their in vitro ADMET profile.
The achievement of the first milestone triggers an undisclosed payment from SKK as well as the continuation of the partnership.
"We are extremely pleased with the quality and speed of the results achieved by 4SC," commented Mr. Satoshi Terao, SKK's Vice President for Research and Development.
"In the last months we have built an excellent relationship and we are looking forward to a continued fruitful collaboration."
"We are very proud that we have reached our first project milestone with SKK," stated Dr Daniel Vitt, CSO of 4SC.
"This success is yet another validation of the efficiency of our drug discovery platform and demonstrates the added value we can offer our partners within the biopharmaceutical industry worldwide."